Max Bayer is a Pharma Reporter at Endpoints News. He covers a wide range of topics within the healthcare sector, including pharmaceutical manufacturing, regulation, consumer health, and public health, with a strong focus on medicine and wellness. His work has been featured in notable publications such as Biotech and Fierce Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Max Bayer's coverage primarily focuses on the healthcare and pharmaceutical industry, specifically on biotech, drug development, FDA approvals, and clinical trials. His articles often contain press releases and cite data from private sector announcements.
To effectively reach out to Max Bayer, consider providing pitches related to groundbreaking advancements in biotechnology or pharmaceuticals with a focus on new drug applications, significant leadership changes within prominent companies in the industry, as well as noteworthy partnerships or deals between key players. Additionally, offering insights supported by reliable data could enhance the appeal of your pitch.
Given that Max Bayer does not have a specific geographic focus mentioned but covers global developments within the healthcare and pharmaceutical sectors, ensure that your pitches reflect international relevance rather than being region-specific.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects.
FDA Commissioner Marty Makary is set to resign after his job status hung in the balance for days.
By: Max Bayer
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Bayer, Drew Armstrong
FDA acting drug chief Tracy Beth Høeg, a vaccine skeptic aligned with HHS Secretary RFK Jr., is expected to depart following Commissioner Marty Makary's exit.
By: Max Bayer
The Trump administration is significantly building the portfolio of drugs available through its direct-to-consumer platform TrumpRx, adding more than 600 generic medicines.
By: Max Bayer
Jilted biotechs coordinated a covert campaign with the Trump administration and Capitol Hill that helped push out FDA Commissioner Marty Makary.
By: Max Bayer
A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb's Hengrui deal.
Lilly's Foundayo and Zepbound gain CVS Caremark formulary coverage, expanding access for 90 million members at $25 monthly co-pays.
By: Max Bayer
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Bayer
Bipartisan Michigan lawmakers unveil a bill subjecting US-China biotech deals to outbound investment screening, citing national security risks.
